Tokyo, Japan

Takeshi Sasoh

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Takeshi Sasoh

Introduction

Takeshi Sasoh is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing formulations that enhance the properties of poorly soluble compounds. His work is characterized by a focus on improving the efficacy of pharmaceutical compositions.

Latest Patents

Takeshi Sasoh holds a patent for a pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. This invention aims to provide a high-dose formulation with improved properties, specifically targeting a poorly soluble basic agent. The composition includes a surfactant and a basic substance, addressing the challenges associated with solubility in pharmaceutical applications.

Career Highlights

Throughout his career, Takeshi has been associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His innovative approach and dedication to research have positioned him as a key figure in the development of new pharmaceutical solutions.

Collaborations

Takeshi Sasoh has collaborated with Akira Kitayama, working together to advance their research and development efforts in the pharmaceutical sector.

Conclusion

Takeshi Sasoh's contributions to pharmaceutical innovation demonstrate his commitment to improving drug formulations and addressing critical challenges in the industry. His work continues to influence the field and pave the way for future advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…